|
|
|
29.05.26 - 11:42
|
Observe Medical ASA - Annual General Meeting held (Cision)
|
|
|
Oslo, 29 May 2026
The annual general meeting of Observe Medical ASA (the "Company" or "Observe Medical", Euronext Expand ticker "OBSRV") was held today, on 29 May 2026 at 10:00 hours (CEST), at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway.
All resolutions were made in accordance with the proposals from the board of directors and the nomination committee.
A copy of the signed minutes from the Annual General Meeting of Observe Medical ASA is attached.
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading...
|
|
|
|
|
|
|
28.05.26 - 08:54
|
Publication of interim report January – March 2026 (Cision)
|
|
|
OSLO, NORWAY – May 28, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for the period January – March 2026. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.
Ronny Hermansen, CEO of Genetic Analysis, comments:
“The first quarter of 2026 was marked by continued progress for Genetic Analysis, with strong growth in recurring GA-map[®] kit sales and further advancement of our microbiome-based diagnostics pipeline. The development confirms the relevance of our standardized GA-map[® ]...
|
|
|
|
|
27.05.26 - 16:12
|
Nordhealth AS has entered into a liquidity provider agreement (Cision)
|
|
|
27th May 2026: Nordhealth AS has entered into a liquidity provider agreement with DNB Carnegie, a part of DNB Bank ASA, for the purpose of enhancing liquidity in the trading of the company's shares, which are listed on Euronext Growth. The agreement is in accordance with, and subject to, the standard requirements of Euronext.
The first day of the liquidity provider programme will be 28th May 2026.
For further information, please contact:
Charles MacBain, CEO charles.macbain@nordhealth.com
Alexander Cram, CFO alexander.cram@nordhealth.com...
|
|
|
27.05.26 - 12:36
|
Arctic Bioscience – Minutes of the Annual General Meeting (Cision)
|
|
|
The Annual General Meeting of Arctic Bioscience AS was held Wednesday 27 May 2026 at 11:00 (CET). All the items on the agenda were addressed and approved. Attached is the minutes of the Annual General Meeting.
Changes to the Board of Directors:
The General Meeting approved the change in the Board of Directors in accordance with the board's proposal, thus the Board of Directors will consist of the following people:
· Tore A. F. Tønseth (chairperson)
· Jan Endre Vartdal
· Harald Nordal
· Marita Holstad
· Olav Sindre Kriken
This information is subject to the disclosure...
|
|
|
26.05.26 - 19:48
|
Annual General Meeting in Nordhealth AS (Cision)
|
|
|
The Annual General Meeting (the "AGM") of Nordhealth AS (the "Company") was held on 26 May 2026 at 10:00 hours (CEST). The minutes of the AGM are attached, as well as the attendance list and voting protocol. All resolutions were approved in accordance with the proposal from the board of directors including, inter alia, a board authorization to increase the share capital with up to NOK 12,028,761.90 by issuance of new shares and to acquire treasury shares for an amount of up to NOK 12,028,761.90. These authorizations will replace the previous authorizations issued at the annual general...
|
|
|
26.05.26 - 15:12
|
Acceptance of Clinical Data for Scientific Publication - UnoMeter[TM] Safeti[TM] Max (Cision)
|
|
|
Oslo, 26 May 2026 – Observe Medical ASA (the "Company" or "Observe Medical") is pleased to announce that an Abstract with in vitro clinical data related to the Company's UnoMeter[TM] Safeti[TM] Max has been accepted for presentation and publication by the International Continence Society.
The accepted Abstract presents findings from in vitro studies evaluating the product's ability to protect patients from Catheter Associated Urinary Tract infection (CAUTI), the most common hospital-acquired infection and a major global healthcare burden, representing a multi-billion-dollar annual cost...
|
|
|
|
|
|
|
22.05.26 - 01:24
|
Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M (GlobeNewswire EN)
|
|
|
Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquartered in Tulsa, Oklahoma. The Agreement grants Fission exclusive worldwide rights to import, market, distribute, and sell HBC's ProGo® salmon-derived bioactive peptide ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel....
|
|
|
|
|
21.05.26 - 17:24
|
Navamedic launches Virono®– the first single-dose over-the-counter cold sore tablet (Cision)
|
|
|
Navamedic ASA (OSE: NAVA) today announces the launch of Virono®, the first over-the-counter single-dose treatment for recurrent cold sores (herpes labialis) in adults. The launch establishes a new OTC treatment category and represents an important step in Navamedic's Nordic Consumer Health growth strategy. Virono is available in Swedish pharmacies from May 2026. Roll-out activities have also been initiated in Finland, while launch in the Netherlands is planned later in 2026.
Highlights
· A new way to treat cold sores: one tablet per outbreak, applied once at the first sign of...
|
|
|
21.05.26 - 07:06
|
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances (Cision)
|
|
|
Oslo, Norway, May 21, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today releases its results for the first quarter of 2026.
Lytix continued to execute on its established development strategy during the first quarter and post-quarter-end period, with progress across its lead asset ruxotemitide and broader oncolytic molecule platform. Clinical development priorities for 2026 and 2027 remain on track, with registrational path planning advancing for ruxotemitide in neoadjuvant melanoma.
Ruxotemitide is supported by a strong and consistent clinical foundation across...
|
|
|
20.05.26 - 21:01
|
Oncoinvent ASA: Grant of share options to member of the Board following AGM (Cision)
|
|
|
Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the “AGM”) of Oncoinvent ASA (the “Company”) earlier today where the nomination committee's proposal for remuneration for the members of the Board was approved.
The AGM approved the following share option remuneration to the Board.
· Chair of the Board: 1,708 share options
· Board members: 854 share options
Share options normally vest over a four-year period as follows: no options shall vest during the first 12 months following the date of the grant, 13/48 of the options shall vest in the 13th month,...
|
|
|
20.05.26 - 17:01
|
Minutes of Annual General Meeting (Cision)
|
|
|
OSLO, NORWAY – 20 May 2026: The Annual General Meeting in Genetic Analysis AS (the "Company") was held on Wednesday 20 May 2026 at 15:00 hours (CEST) at the Company's premises in Ulvenveien 80B, Oslo.
1. Opening of the meeting
The meeting was opened by chairperson Morten Jurs, who recorded the list of attending shareholders. In total 23,896,887 shares out of the Company's 69,087,041 shares were present, corresponding to 34.59% of the total number of shares and votes of the Company.
2. Election of a chairperson and a person to co-sign the minutes
Chairperson Morten Jurs was elected...
|
|
|
|
|
20.05.26 - 11:18
|
Oncoinvent ASA: Minutes from Annual General Meeting (Cision)
|
|
|
20 May 2026, Oslo Norway: The Annual general meeting of the Company was held today, 20 May 2026, by electronic means through Lumi AGM. All proposals on the agenda were adopted in accordance with the proposals set out in the notice dated 28 April 2026.
The complete minutes of the ordinary general meeting are attached to this release and are also available on the Company's website, https://www.oncoinvent.com/investors/general-meetings/. (https://www.oncoinvent.com/investors/general-meetings/)
Oncoinvent ASA - Minutes of Annual General Meeting 20 May 2026 (https://mb.cision.com/Public/...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
